2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension

S. Kjeldsen
{"title":"2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension","authors":"S. Kjeldsen","doi":"10.1159/000076262","DOIUrl":null,"url":null,"abstract":"Accessible online at: www.karger.com/hed S.E.K. is a member of the Council of the European Society of Hypertension and of the Writing Group of the 2003 European Society of Hypertension-European Society of Cardiology Guidelines. Hypertension, hypercholesterolemia and smoking are the most important risk factors for cardiovascular disease and death. For the first time, the European sister organizations European Society of Hypertension (ESH) and European Society of Cardiology (ESC) have come out with joint guidelines regarding the detection and treatment of hypertension – printed in this special issue of Heart Drug. It is realized that cardiologists play a key role more than ever in the care of hypertensive patients and an increasingly important role as educators in this field. The Guidelines Paper was developed by experts in the cardiovascular field and key opinion leaders from most countries in Europe. The guidelines are based on the 1999 International Society of Hypertension/World Health Organization Guidelines and they are endorsed by the International Society of Hypertension. It is a thorough educational document with more than 300 quotations of important publications. The new guidelines integrate detection and treatment of other important risk factors, including diabetes. A new issue in the risk assessment of hypertensive patients and for the first time included in the guidelines is the detection of target organ damage like left ventricular hypertrophy, arterial plaque, microalbuminuria or slightly elevated serum creatinine. With a 10-year risk of cardiovascular disease of 20% or more, drug treatment for hypertension is always warranted, and a statin and acetylsalicylic acid would usually be indicated. In contrast to the 2003 American Guidelines (JNC-7), in these guidelines, a number of different drugs are considered evidence-based first-line treatment, and combination treatment is strongly recommended to reach blood pressure targets. A shortened ‘Practical Guidelines’ has been developed and will be translated into various European languages. It is expected that the 2003 ESH-ESC Guidelines will soon be implemented in all countries within the area of the European Union. Hopefully, these clinically oriented guidelines will provide the basis for improved hypertension care and control in Europe!","PeriodicalId":87985,"journal":{"name":"Heartdrug : excellence in cardiovascular trials","volume":"38 1","pages":"5 - 5"},"PeriodicalIF":0.0000,"publicationDate":"2004-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heartdrug : excellence in cardiovascular trials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000076262","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 10

Abstract

Accessible online at: www.karger.com/hed S.E.K. is a member of the Council of the European Society of Hypertension and of the Writing Group of the 2003 European Society of Hypertension-European Society of Cardiology Guidelines. Hypertension, hypercholesterolemia and smoking are the most important risk factors for cardiovascular disease and death. For the first time, the European sister organizations European Society of Hypertension (ESH) and European Society of Cardiology (ESC) have come out with joint guidelines regarding the detection and treatment of hypertension – printed in this special issue of Heart Drug. It is realized that cardiologists play a key role more than ever in the care of hypertensive patients and an increasingly important role as educators in this field. The Guidelines Paper was developed by experts in the cardiovascular field and key opinion leaders from most countries in Europe. The guidelines are based on the 1999 International Society of Hypertension/World Health Organization Guidelines and they are endorsed by the International Society of Hypertension. It is a thorough educational document with more than 300 quotations of important publications. The new guidelines integrate detection and treatment of other important risk factors, including diabetes. A new issue in the risk assessment of hypertensive patients and for the first time included in the guidelines is the detection of target organ damage like left ventricular hypertrophy, arterial plaque, microalbuminuria or slightly elevated serum creatinine. With a 10-year risk of cardiovascular disease of 20% or more, drug treatment for hypertension is always warranted, and a statin and acetylsalicylic acid would usually be indicated. In contrast to the 2003 American Guidelines (JNC-7), in these guidelines, a number of different drugs are considered evidence-based first-line treatment, and combination treatment is strongly recommended to reach blood pressure targets. A shortened ‘Practical Guidelines’ has been developed and will be translated into various European languages. It is expected that the 2003 ESH-ESC Guidelines will soon be implemented in all countries within the area of the European Union. Hopefully, these clinically oriented guidelines will provide the basis for improved hypertension care and control in Europe!
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
2003年欧洲高血压学会-欧洲心脏病学会动脉高血压管理指南
S.E.K.是欧洲高血压学会理事会和2003年欧洲高血压学会-欧洲心脏病学会指南写作小组的成员。高血压、高胆固醇血症和吸烟是心血管疾病和死亡的最重要危险因素。欧洲姐妹组织欧洲高血压学会(ESH)和欧洲心脏病学会(ESC)首次发布了关于高血压检测和治疗的联合指南,并发表在这期《心脏药物》特刊上。人们认识到,心脏病专家在高血压患者的护理中发挥着比以往任何时候都重要的作用,并且在这一领域作为教育者的作用越来越重要。该指南文件是由欧洲大多数国家心血管领域的专家和主要意见领袖制定的。该指南以1999年国际高血压学会/世界卫生组织指南为基础,并得到了国际高血压学会的认可。这是一份全面的教育文件,引用了300多篇重要出版物。新的指南整合了其他重要危险因素的检测和治疗,包括糖尿病。高血压患者风险评估的一个新问题是目标器官损伤的检测,如左心室肥厚、动脉斑块、微量白蛋白尿或血清肌酐轻微升高。如果10年心血管疾病风险在20%或以上,高血压的药物治疗总是有必要的,通常需要他汀类药物和乙酰水杨酸。与2003年美国指南(JNC-7)相反,在这些指南中,许多不同的药物被认为是基于证据的一线治疗,并且强烈建议联合治疗以达到血压目标。已编制了一份简短的“实用指南”,并将被翻译成各种欧洲语言。预计2003年hse - esc准则将很快在欧洲联盟区域内的所有国家实施。希望这些临床导向的指南将为欧洲改善高血压护理和控制提供基础!
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Safety of Bone Marrow Stem Cell Mobilization Induced by Granulocyte-Colony Stimulating Factor: 30 Days’ Blinded Clinical Results from the Stem Cells in Myocardial Infarction (STEMMI) Trial Rationale and Design of the OACIS-LIPID Study That Evaluates Early Use of Pravastatin in Acute Myocardial Infarction Hyperglycemia after Acute Ischemic Stroke: Prediction, Significance and Immediate Control with Insulin-Potassium-Saline-Magnesium Infusions Nicorandil – Review of Pharmacological Properties and Clinical Applications Can Statins Be Considered as a Tertiary Level Agent in Patients with Failure of Conventional Oral Hypoglycemic Agents?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1